Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

Which healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN).

Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Amgen (AMGN – Research Report). The company’s ...